Chongqing Lummy Pharmaceutical Co., Ltd. (SHE:300006)
China · Delayed Price · Currency is CNY 5.09
+0.12 (2.41%)
Feb 3, 2026, 3:04 PM CST
SHE:300006 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 757.96 | 782.54 | 874.25 | 865.46 | 1,211 | 1,578 |
Other Revenue | 13.06 | 13.06 | 21.34 | 19.13 | 14.61 | 5.92 |
| 771.02 | 795.6 | 895.59 | 884.59 | 1,225 | 1,584 | |
Revenue Growth (YoY) | -9.98% | -11.16% | 1.24% | -27.80% | -22.63% | -14.82% |
Cost of Revenue | 334.44 | 296.54 | 283.15 | 238.66 | 380.93 | 526.96 |
Gross Profit | 436.58 | 499.06 | 612.44 | 645.93 | 844.3 | 1,057 |
Selling, General & Admin | 464.63 | 531.63 | 596.69 | 659.59 | 854.25 | 1,036 |
Research & Development | 59.55 | 64.73 | 99.81 | 80.65 | 100.2 | 107.36 |
Other Operating Expenses | -12.82 | -24.68 | -25.67 | 17.18 | 24.7 | 25.36 |
Operating Expenses | 512.31 | 573.74 | 669.15 | 751.82 | 977.73 | 1,172 |
Operating Income | -75.73 | -74.69 | -56.71 | -105.89 | -133.43 | -115.18 |
Interest Expense | -13.62 | -11.13 | -12.47 | -20.35 | -32.08 | -83.19 |
Interest & Investment Income | 26.26 | 29.65 | 121.66 | 18.71 | 61.45 | 9.74 |
Currency Exchange Gain (Loss) | 0.44 | 0.44 | 0.57 | 2.77 | -0.77 | -5.03 |
Other Non Operating Income (Expenses) | -39.51 | -9.31 | -5.48 | -45.43 | -25.12 | -19.19 |
EBT Excluding Unusual Items | -102.17 | -65.04 | 47.56 | -150.19 | -129.95 | -212.85 |
Impairment of Goodwill | - | - | - | - | - | -48.84 |
Gain (Loss) on Sale of Investments | -17.92 | -18.88 | -1.28 | - | - | -36.18 |
Gain (Loss) on Sale of Assets | 0.44 | 0.49 | 0.45 | 0.26 | -0.03 | 0.65 |
Asset Writedown | -26.4 | -25.75 | -0.71 | -0.1 | -0.51 | -117.98 |
Legal Settlements | - | - | -51.76 | - | - | - |
Other Unusual Items | 33.63 | 33.63 | 9.34 | 74.78 | 24.52 | 71.6 |
Pretax Income | -112.43 | -75.54 | 3.59 | -75.25 | -105.96 | -343.6 |
Income Tax Expense | -2.94 | 4.55 | 13.61 | 1.04 | -0.03 | 1.05 |
Earnings From Continuing Operations | -109.49 | -80.09 | -10.02 | -76.28 | -105.94 | -344.66 |
Minority Interest in Earnings | 2.18 | -7.72 | 1.09 | 7.58 | 5.41 | 17.89 |
Net Income | -107.3 | -87.8 | -8.93 | -68.71 | -100.53 | -326.76 |
Net Income to Common | -107.3 | -87.8 | -8.93 | -68.71 | -100.53 | -326.76 |
Shares Outstanding (Basic) | 1,055 | 1,055 | 1,050 | 1,055 | 995 | 812 |
Shares Outstanding (Diluted) | 1,055 | 1,055 | 1,050 | 1,055 | 995 | 812 |
Shares Change (YoY) | 0.39% | 0.48% | -0.48% | 6.03% | 22.54% | 0.01% |
EPS (Basic) | -0.10 | -0.08 | -0.01 | -0.07 | -0.10 | -0.40 |
EPS (Diluted) | -0.10 | -0.08 | -0.01 | -0.07 | -0.10 | -0.40 |
Free Cash Flow | -50.86 | 106.41 | 22.21 | -11.05 | 69.63 | 180.01 |
Free Cash Flow Per Share | -0.05 | 0.10 | 0.02 | -0.01 | 0.07 | 0.22 |
Gross Margin | 56.62% | 62.73% | 68.38% | 73.02% | 68.91% | 66.72% |
Operating Margin | -9.82% | -9.39% | -6.33% | -11.97% | -10.89% | -7.27% |
Profit Margin | -13.92% | -11.04% | -1.00% | -7.77% | -8.21% | -20.64% |
Free Cash Flow Margin | -6.60% | 13.37% | 2.48% | -1.25% | 5.68% | 11.37% |
EBITDA | -39.05 | -25.67 | 8.76 | -35.29 | -63.41 | -6.4 |
EBITDA Margin | -5.06% | -3.23% | 0.98% | -3.99% | -5.18% | -0.40% |
D&A For EBITDA | 36.69 | 49.02 | 65.47 | 70.6 | 70.01 | 108.78 |
EBIT | -75.73 | -74.69 | -56.71 | -105.89 | -133.43 | -115.18 |
EBIT Margin | -9.82% | -9.39% | -6.33% | -11.97% | -10.89% | -7.27% |
Effective Tax Rate | - | - | 378.71% | - | - | - |
Revenue as Reported | 771.02 | 795.6 | 895.59 | 884.59 | 1,225 | 1,584 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.